143 related articles for article (PubMed ID: 22939006)
1. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
2. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
Kellner M; Muhtz C; Demiralay C; Husemann J; Koelsch W; Yassouridis A; Wiedemann K
J Psychiatr Res; 2009 Mar; 43(6):642-8. PubMed ID: 18930474
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
[TBL] [Abstract][Full Text] [Related]
4. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.
Agorastos A; Kellner M; Stiedl O; Muhtz C; Wiedemann K; Demiralay C
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522396
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Stahl SM; Gergel I; Li D
J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
[TBL] [Abstract][Full Text] [Related]
7. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
8. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; Scheepmakers A
Psychopharmacology (Berl); 1997 Feb; 129(4):357-64. PubMed ID: 9085405
[TBL] [Abstract][Full Text] [Related]
9. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
10. Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers.
Maron E; Tõru I; Tasa G; Must A; Toover E; Lang A; Vasar V; Shlik J
Neurosci Lett; 2008 Dec; 446(2-3):88-92. PubMed ID: 18832011
[TBL] [Abstract][Full Text] [Related]
11. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.
Shlik J; Aluoja A; Vasar V; Vasar E; Podar T; Bradwejn J
J Psychiatry Neurosci; 1997 Nov; 22(5):332-40. PubMed ID: 9401314
[TBL] [Abstract][Full Text] [Related]
12. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
13. Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study.
Coryell W; Rickels H
J Clin Psychopharmacol; 2009 Apr; 29(2):174-8. PubMed ID: 19512981
[TBL] [Abstract][Full Text] [Related]
14. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
[TBL] [Abstract][Full Text] [Related]
15. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
16. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M
Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917
[TBL] [Abstract][Full Text] [Related]
17. The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study.
Outhred T; Das P; Dobson-Stone C; Felmingham KL; Bryant RA; Nathan PJ; Malhi GS; Kemp AH
Aust N Z J Psychiatry; 2014 Dec; 48(12):1115-25. PubMed ID: 24810870
[TBL] [Abstract][Full Text] [Related]
18. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
19. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
[TBL] [Abstract][Full Text] [Related]
20. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
